This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walsh, L. J. Articles by Tattersfield, A. E. Search for Related Content PubMed PubMed Citation Articles by Walsh, L. J. Articles by Tattersfield, A. E.

The Impact of Oral Corticosteroid Use on Bone Mineral Density and Vertebral Fracture

Division of Respiratory Medicine and Radiology, City Hospital; and Department of General Practice, Queens Medical Centre, Nottingham, United Kingdom

Correspondence and requests for reprints should be addressed to Dr. Lesley J. Walsh, M.D., M.R.C.P., Consultant Physician, Sandwell and West Birmingham Hospitals, NHS Trust, Lyndon, West Bromwich, West Midlands, B71 4HJ, UK. E-mail: lesley.walsh{at}swellhot.wmids.nhs.uk

The use of oral corticosteroids is associated with an increased risk of fracture, but there is limited information on the relationship between corticosteroid dose, bone mineral density (BMD), and fracture. We examined this relationship in a community population (more than 50 years) taking oral corticosteroids for chronic lung disease. Details of corticosteroid use and lifestyle were obtained by questionnaire, general practice records, and patient interview. BMD was assessed at the lumbar spine and femur and vertebral fracture by morphometric X-ray absorptiometry. Of the 117 patients who participated (median age, 69), 48% were female. Fifty-eight percent had osteoporosis (a T score of less than -2.5), and 61% had a vertebral fracture. The presence of vertebral fracture was related to BMD at the femoral neck, with an odds ratio of 1.6 for a 1 SD reduction in BMD. The cumulative prednisolone dose ranged from 3.4 to 175 g and was strongly associated with vertebral fracture, with the odds ratio between the highest and lowest dose quartiles being 4.4 (95% confidence interval, 1.04, 18.8). The difference in femoral neck BMD between the same dose quartiles was only modest, however (0.5 SD; 95% confidence interval, 0.09, 0.94). In patients taking long-term oral corticosteroids for chronic lung disease, the relationship between vertebral fracture risk and BMD is similar to that seen in other populations. Cumulative prednisolone dose is strongly related to fracture risk, and this effect is independent of its more modest impact on BMD.

Key Words: corticosteroids • bone • dose-related effects • fracture

This article has been cited by other articles:

				K. G. Saag, E. Shane, S. Boonen, F. Marin, D. W. Donley, K. A. Taylor, G. P. Dalsky, and R. Marcus Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis N. Engl. J. Med., November 15, 2007; 357(20): 2028 - 2039. [Abstract] [Full Text] [PDF]

				A. Hiwatashi and P.L. Westesson Patients with Osteoporosis on Steroid Medication Tend to Sustain Subsequent Fractures AJNR Am. J. Neuroradiol., June 1, 2007; 28(6): 1055 - 1057. [Abstract] [Full Text] [PDF]

				H. Gunen, S. S. Hacievliyagil, O. Yetkin, G. Gulbas, L. C. Mutlu, and E. In The role of nebulised budesonide in the treatment of exacerbations of COPD Eur. Respir. J., April 1, 2007; 29(4): 660 - 667. [Abstract] [Full Text] [PDF]

				M.I. Syed, N.A. Patel, S. Jan, A. Shaikh, B. Grunden, and K. Morar Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis. AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1938 - 1943. [Abstract] [Full Text] [PDF]

				F G Irani, J P Morales, T Sabharwal, R Dourado, A Gangi, and A Adam Successful treatment of a chronic post-traumatic 5-year-old osteoporotic vertebral compression fracture by percutaneous vertebroplasty Br. J. Radiol., March 1, 2005; 78(927): 261 - 264. [Abstract] [Full Text] [PDF]

				A. E. Tattersfield, T. W. Harrison, R. B. Hubbard, and K. Mortimer Safety of Inhaled Corticosteroids Proceedings of the ATS, November 1, 2004; 1(3): 171 - 175. [Abstract] [Full Text] [PDF]

				H. Andreassen and J. Vestbo Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective Eur. Respir. J., November 2, 2003; 22(46_suppl): 2S - 4s. [Abstract] [Full Text] [PDF]

				J. E. Shea, S. C. Miller, D. C. Poole, and J. P. Mattson Cortical bone dynamics, strength, and densitometry after induction of emphysema in hamsters J Appl Physiol, August 1, 2003; 95(2): 631 - 634. [Abstract] [Full Text] [PDF]

				M. J. Tobin Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332. [Full Text] [PDF]

				M. J. Tobin Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 356 - 370. [Full Text] [PDF]

				Robin Goodfellow (41-12) Rheumatology, December 1, 2002; 41(12): 1460 - 1460. [Full Text] [PDF]